Program
JK07
A development code.
Its studies are mostly in Heart Failure, led by Shenzhen Salubris Pharmaceuticals.
Furthest: phase 2, since Apr 12, 20244 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 41 open or running | phase 2since Apr 12, 2024 | Dec 17, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2019First study: phase 1 study in Heart FailureFirst studyNCT04210375 · 14 enrolled · United States
- Mar 14, 2022Phase 1 study in Heart FailureNCT05322616 · United States
- Apr 12, 2024Phase 2 study in Heart FailureNCT06369298 · 282 enrolled · United States, Canada, China and more
- Aug 20, 2025Phase 2 study in Heart FailureNCT07221513 · United States
TargetBeta
EGF →read by rule
“JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.”study text, by rule · the study
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07221513Heart Failure · United States | 2 | Withdrawn | Apr 16, 2026 | 0 |
| NCT06369298Heart Failure · United States, Canada, China and more | 2 | Active, not recruiting | Oct 31, 2026 | 282 |
| NCT05322616Heart Failure · United States | 1 | Withdrawn | May 26, 2023 | 0 |
| NCT04210375Heart Failure · United States | 1 | Completed | Jun 8, 2023 | 14 |
How it is read
Names in the registry
- “JK07”, 4 entries
Codes read as this program: JK07.
Conditions, from the studies’ own filings
- Heart Failure, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.